AboutUs
News
Career
Donate
Contact

Hematology & Oncology

Our division participates in multiple cancer-related clinical trials that offer novel treatment modalities for eligible patients. Many clinical trials are still open for patient enrollment and include studies investigating efficacies of various treatment regimens for breast, lung, and colon cancer. Some of the clinical trails are listed below. For further information on these trials or for eligibility, please contact Maria Rapuzzi, RN, MPA, Research manager, Oncology Division.

Fellowship Program Director
Frank Forte, MD - Division Director

Key Clinical Faculty
Quan Dai, MD
Meekoo Dhar, MD
Philip Friscia, MD
Shilpi Gupta, MBBS
Marcel Odaimi, MD - Chairman of Oncology Performance Improvement, Chairman of Tumor Board
Terenig Terjanian, MD - Director Hematology/Oncology-South Site, Chairman of Cancer Committee

List of Clinical Trials Open for Accrual

Colon Cancer

  • Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer, PI: Dr. Forte
  • A Phase III Trial or Irinotecan/ 5-FU/ Leucovorin or Oxaliplatin/ 5-FU/Leucovorin with Bevacizumano Cextuximab (C225) For Patients With Treated Metastatic Adenocarcinom the Colon or Rectum, PI: Dr. Odaimi

Lung Cancer

  • A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuzimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), PI: Dr. Friscia
  • ECOG-5508 Randomized Phase III study of Maintenance Therapy with Bevacizumab, Premetrexed or a combination of Bevacizumab and Premetrexed following carboplatin, paclitaxel and bevacizumab for advanced non-squamous NSCLC, PI: Dr. Friscia

Metastatic Cancer

(Breast, Prostate, Multiple Myeloma)

  • A Randomized Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zaledronic Acid in Metastatic Cancer, PI: Dr. Forte

Renal Cancer

  • A Randomized Double Blinded, Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma, PI: Dr. Forte
  • Randomized Phase III Trial comparing Everolimus plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors (CALGB 90802), PI: Dr. Forte

Invited Presentations

  • Azab, B, BBhatt, V, Vonfrolio, S, Bachir, R, Rubinshteyn, V, Habeshy, A, Patel, J, Picon, A, Bloom, S. Value of the Pre-treatment Albumin to globulin Ratio in Predicting Long-term Mortality in Breast Cancer Patients. Poster presented 2012 Society of Surgical Oncology Annual Cancer Symposium, March 22-24, 2012, Orlando, Fl.
  • Bhatt, V, Murukutla, S, Naqi, M, Polepalli, S, Pant, S, Kedia, S, Terenig, T. IgM Multiple myeoloma (MM) or Waldenstrom’s Macroglobulinemia (WM) is the big question? Accepted for poster presentation National ACP 12/1/11.
  • Hassan, S, Popalzai, M, Yu, E, Odaimi, M. Inflammatory Dermatitis with Motor Neuropathy and Myopathy Responsive to CLL Treatment: Case report. Accepted for poster presentation at National ACP 12/1/11
  • Bhatt, V, Naqi (Rizvi), M, Misra S, Baraula R, Popalzai M, Paramanathan K, Dai Q, Khoueiry G, Olkovsky Y. T-Cell Acute Lymphoblastic Leukemia Presenting with Sudden Onset Right Oculomotor Nerve Palsy with Normal Neuroradiography and Cerebrospinal Fluid Studies. Accepted for poster presentation NYACP Scientific Meeting, Rye Brook, NY, 5/26/11
  • Siddique, M, Popalzai, M, Aoun, N, Maroun, R, Awasum, M, Dai, Q. Precursor B-cell Acute Lymphoblastic Leukemia Presenting as Obstructive Jaundice. Accepted for poster presentation at NYACP 3/1/11
  • Maarouf O, Waked A, Geara A, Khoueiry G, AbiRached J, Ayoub I, Terjanian T, Lafferty J, Dunne E, Smith M, El Sayegh S. An analysis of the diet of hemodialysis patients during a dialysis specific FFQ. - Presented at the New York American College of Physicians' Upstate Scientific Meeting on April 10, 2010.
  • Mourad M, Aoun N, Baz W, Friscia P. Humoral hypercalcemia of malignancy (HHM) in association with mucoepidermoid carcinoma of the parotid gland. - Presented at the New York American College of Physicians' Upstate Scientific Meeting on April 10, 20

Publications

© 2014 Staten Island University Hospital. All Rights Reserved.

Privacy Policy | Sitemap | Notice of Privacy Practices | Compliance & Patient Privacy | Disclaimer